The pro-oncogenic potential of RUNX2 is supported by several findings: chromosome amplification of the genomic region containing RUNX2 is found in osteosarcoma [74] and increased expression of RUNX2 is associated with poor chemo-sensitivity in osteosarcomas [75], progression of prostate cancer in patients [76], and metastasis in breast cancer MDA-MB-231 cells [77]. This evidence concerns the gene RUNX2 and prostate cancer.